Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | KHK | P50053 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1981727 | 0.85 | SLC6A4 (0.34) | HTR2AHTR2CKHK | |
| SCHEMBL705011 | 0.81 | NLRP3 (0.47) | PDGFRACDK5TYRO3NLRP3HTR2A | |
| SCHEMBL5678073 | 0.74 | NLRP3 (0.38) | PDGFRACDK5TYRO3NLRP3 | |
| SCHEMBL7772318 | 0.74 | NLRP3 (0.38) | PDGFRACDK5TYRO3NLRP3 | |
| SCHEMBL906047 | 0.74 | HTR2C (0.51) | PDGFRACDK5TYRO3HTR2AHTR2C | |
| SCHEMBL4507507 | 0.73 | GRM4 (0.43) | PDGFRACDK5TYRO3KHK | |
| SCHEMBL683164 | 0.72 | ADORA2A (0.43) | PDGFRACDK5TYRO3HTR2AHTR2C | |
| SCHEMBL23467048 | 0.70 | NLRP3 (0.40) | NLRP3HTR2AHTR2C | |
| SCHEMBL683169 | 0.70 | ADORA2A (0.46) | PDGFRACDK5TYRO3KHK | |
| Ammonia Solution, Strong SCHEMBL906049 | 0.69 | ADORA2A (0.45) | PDGFRACDK5TYRO3KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1129078-B1 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RES LTD (GB) | 2006-03-15 | — | — | EP | claimed |
| US-6552062-B1 | For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity | VERNALIS RESEARCH LIMITED (GB) | 2003-04-22 | — | — | US | claimed |
| EP-1129078-A2 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RESEARCH LIMITED (GB) | 2001-09-05 | — | — | EP | claimed |
| WO-2000012481-A2 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY________________ | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| EP-1129078-B1 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RES LTD (GB) | 2006-03-15 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| US-6552062-B1 | For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity | VERNALIS RESEARCH LIMITED (GB) | 2003-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | PDGFRA 1590/4885CDK5 633/4885TYRO3 1977/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | PDGFRA 1590/4885CDK5 633/4885TYRO3 1977/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | PDGFRA 1590/4885CDK5 633/4885TYRO3 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.